石藥(01093.HK)抗腫瘤納米藥物獲藥監局藥品註冊批件
石藥集團(01093.HK)公布,附屬公司石藥集團中諾藥業(石家莊)開發的「Mitoxantrone Hydrochloride Liposome注射液 (10ml:10mg)」,近日已獲得中國國家藥品監督管理局頒發的藥品註冊批件,用於治療復發或難治的外周T細胞淋巴瘤(PTCL)。
該產品為集團自主研發的抗腫瘤納米藥物,同時亦是全球首個上市的Mitoxantrone納米藥物,在美國已獲得臨床許可,並取得孤兒藥資格,相關的臨床試驗正在進行中。集團預期,該產品有望成為重磅產品,並為腫瘤患者帶來新用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.